We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genetically Engineered Mouse Model Mimics Rare Human Bone Disorder

By LabMedica International staff writers
Posted on 25 Jan 2016
A model for the study of the rare bone disorder Hajdu-Cheney syndrome was developed by genetically engineering a line of mice to express a specific Notch2 mutation.

Notch2 is a member of the notch family of transmembrane proteins that share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple, different domain types. More...
Notch family members play a role in a variety of developmental processes by controlling cell fate decisions. The Notch signaling network is an evolutionarily conserved intercellular signaling pathway that regulates interactions between physically adjacent cells. Mutations within the last coding exon of NOTCH2 have been shown to be the main cause of the Hajdu-Cheney syndrome.

Hajdu-Cheney syndrome—an exceedingly rare disease, with fewer than 100 cases ever described—is characterized by osteoporosis and fractures. Development of this disease is associated with NOTCH2 (neurogenic locus notch homolog protein 2) mutations that result in a truncated stable protein that avoids deactivation by the cell.

To study the relationship between the NOTCH2 mutation and the disease syndrome, investigators at the University of Connecticut (Storrs, USA) created a mouse model that reproduced Hajdu-Cheney syndrome by introducing a mutation in the NOTCH2 locus leading to a change at the amino acid level.

They reported in the December 1, 2015, online edition of the Journal of Biological Chemistry that heterozygous mutants were smaller and had shorter femurs than controls; and at one month of age exhibited cancellous and cortical bone osteopenia (lower than normal bone mineral density). As the mice matured, cancellous bone volume was restored partially in male but not female mice, whereas cortical osteopenia persisted in both sexes. Cancellous bone was found to have an increased number of osteoclasts (bone cells that break down bone tissue) and bone resorption, without a decrease in osteoblast (bone precursor cells) number or bone formation.

"Until now, nobody understood why people afflicted with the disease had osteoporosis and fractures," said first author Dr. Ernesto Canalis, professor of orthopedic surgery at the University of Connecticut. "There are a few symptoms of the disease in humans—such as shortened fingers and oddly shaped skull bones—that the mice do not display. But overall, the mouse model is a very good model of the human disease."

Related Links:
University of Connecticut



Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Staining System
RAL DIFF-QUIK
New
PlGF Test
Quidel Triage PlGF Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.